Beta-Blockers for Pyogenic Granuloma: A Systematic Review of Case Reports, Case Series, and Clinical Trials

Area of Science:

• Dermatology
• Pharmacology
• Vascular Biology

Background:

• Pyogenic granuloma (PG) is a benign vascular proliferation requiring treatment due to bleeding, ulceration, and cosmetic concerns.
• Traditional treatments like surgery, cryotherapy, and electrocautery have high recurrence rates.
• Beta-blockers, effective for infantile hemangioma, are being explored for PG due to shared beta-adrenergic receptor expression.

Purpose of the Study:

• To review the existing literature on the efficacy of topical beta blockers for treating pyogenic granuloma.
• To analyze case reports, case series, and open-label trials investigating topical beta blocker use in PG.

Main Methods:

• Literature search and systematic review of published studies.
• Analysis of data from case reports, case series, and open-label single-arm trials.
• Focus on topical beta blockers like timolol, propranolol, and betaxolol for PG treatment.

Main Results:

• Topical beta blockers have demonstrated effectiveness in treating pyogenic granuloma.
• Studies indicate a favorable treatment profile with potential for reduced recurrence compared to conventional therapies.
• Various topical beta blockers were utilized, showing consistent therapeutic outcomes across different study designs.

Conclusions:

• Topical beta blockers represent an attractive and effective therapeutic option for pyogenic granuloma.
• Further research and clinical trials are warranted to establish standardized protocols and long-term efficacy.
• The findings support the use of topical beta blockers as a viable alternative for managing PG.